A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences

Digestive Diseases and Sciences

Volumn 50, Issue 9, 2005, Pages 1625-1631

  Ando, Takashi ^a   Kato, Haruki ^a   Sugimoto, Naohito ^a   Nagao, Yasuyuki ^a   Seto, Nobuyuki ^a   Hongo, Hitoshi ^a   Kajikawa, Hirokazu ^a   Isozaki, Yutaka ^b   Shimozawa, Makoto ^b   Naito, Yuji ^b   Yoshida, Norimasa ^b   Ishizaki, Takashi ^c   Yoshikawa, Toshikazu ^b  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

CYP2C19; Endoscopy; Gastric ulcer healing; Mucosal repair; Omeprazole; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; RABEPRAZOLE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOSCOPY; FEMALE; FLATULENCE; GENOTYPE; HEADACHE; HOMOZYGOSITY; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA; STOMACH MUCOSA LESION; STOMACH ULCER; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; STOMACH ULCER; TREATMENT OUTCOME;

EID: 23944512871     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2907-z     Document Type: Article

References (24)

1. DeVault KR: Gastroesophageal reflux disease: extraesophageal manifestations and therapy. Semin Gastrointest Dis 12:46-51, 2001
2. Jones R, Bytzer P: Review article: Acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care. Aliment Pharmacol Ther 15:765-772, 2001
3. Besancon M, Simon A, Sachs G, Shin JM: Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272:22438-22446, 1997
4. Ishizaki T, Horai Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 13(Suppl 3):27-36, 1999
5. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L: Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:411-426, 2001
6. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727, 2001
7. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937, 2001
8. Andersson T, Holmberg J, Rohss K, Walan A: Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 45:369-375, 1998
9. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M: Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391-396, 1997
10. Furuta T, Ohashi K, Kosuge K, Zhao X-J, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561, 1999
11. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin S-G: Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266-273, 2001
12. Kupfer A, Preisig R: Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759, 1984
13. Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76, 1989
14. Bertilsson L: Geographic/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209, 1995
15. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422, 1994
16. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598, 1994
17. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243-247, 1998
18. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effects of rabeprazole, lansoprazole, and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 16:1811-1817, 2002
19. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666, 1996
20. About NIH Image. Bethesda, MD: National Institutes of Health. Available at: http://rsb.info.nih.gov/nih-image/
21. Nakamura Y, Endo C, Sato M, Sakurada A, Watanabe S, Sakata R, Kondo K: A new technique for endobronchial ultrasonography and comparison of two ultrasonic probes. Chest 126:192-197, 2004
22. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Anderson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16:214-215, 1994
23. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408, 1985
24. McColl KEL, Kennerley P: Proton pump inhibitors - differences emerge in hepatic metabolism. Dig Liver Dis 34:461-167, 2002